Navigation Links
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Date:6/11/2008

infusion daily for five days of a 21-day cycle in patients with advanced pancreatic cancer who have progressed on gemcitabine or a gemcitabine-containing regimen.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to the therapeutic and commercial potential of PX-12; future clinical development plans; the details of clinical trials; and the anticipated future size of the market for PX-12. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-12. There can be no guarantee that the results of earlier trials will be predictive of
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to receive milestone payment
2. Oncothyreon Reports First Quarter 2008 Financial Results
3. Oncothyreon files investigational new drug application for PX-866 oncology compound
4. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
5. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
6. Oncothyreon announces effectiveness of shelf registration statement
7. Oncothyreon announces issuance of patent for PX-867
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon reports full year and fourth quarter 2007 financial results
10. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
11. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... is pleased to announce that the Company will be ... 2015 to be held in London, UK ... and Mr. James Mellon , a director of ... the key programs at its subsidiaries, Portage Pharmaceuticals Ltd. ...
(Date:4/16/2015)... A new infographic compiles useful information ... institutions to learn how Apple’s new framework can change ... is ideal since Apple made Research Kit ... open-source framework for developing medical research apps that Apple ... researchers to collect secure clinical data and communicate via ...
(Date:4/16/2015)...  EMD Serono today announced the US biopharmaceutical ... , appointed Alise Reicin , MD, ... Development.  Dr. Reicin brings extensive research and early/late ... Immunology. She is an accomplished pharmaceutical executive with ... President in various capacities across R&D at MSD ...
(Date:4/16/2015)... April 16, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... developing non-toxic DCVax® personalized immune therapies for cancer, ... the Loncar Cancer Immunotherapy Index (LCINDX), a professional ... the immunotherapy field within the biotechnology space.  ... top 25 companies" in the immunotherapy space, including ...
Breaking Biology Technology:Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... NEW YORK, Oct. 10, 2011 In response to Rubicon,s ... E. Sandell sent today the following letter to Rubicon,s Board ... 3 7 - 9 Fanshawe Street Auckland New Zealand Attn: ... Dear Gentlemen: As you are aware, funds ...
... Iceland, October 9, 2011 Scientists at deCODE ... and the USA today report the discovery of low frequency ... gout, a common inflammatory arthritis, and serum uric acid levels. ... is published today in the online edition of Nature ...
... In support of Breast Cancer Awareness LensWay.co.uk will ... There are over 50 styles to choose from and starting ... range of pink glasses please visit the following page: ... For women in the UK breast cancer is the most ...
Cached Biology Technology:Sandell Asset Management Seeks Sale of Rubicon & Tenon, Expansion of Board 2Sandell Asset Management Seeks Sale of Rubicon & Tenon, Expansion of Board 3deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels 2deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels 3Buy Pink Glasses From LensWay and £20 Will be Donated to Breast Cancer Research 2
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/23/2015)... SoundView Technology Group issues a new research update ... Wocket smart wallet. SoundView was one of the selected user groups ... the Wocket in multiple scenarios and outlets. ... retailers, making both debit and credit card payments.  ... the company meets their plans in 2015, it would push ...
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... the nutrient-poor soils in which they grow by trapping ... of the genus Nepenthes were thought to capture their ... paper in this weeks PLoS ONE, Laurence Gaume and ... CNRS, working respectively in the University of Montpellier and ...
... A joint Yale-Peking University center that aims to ... will receive five years of continued and expanded support ... technology. The company will fund student exchanges and ... Peking-Yale Joint Center (PYC) for Plant Molecular Genetics and ...
... CO 2 emissions from using coal are set to double ... of mitigating global climate change. In view of the essential ... minimise emissions where coal is used. The British ... Coal (NZEC) Phase 1 study in Beijing, China today. The aim ...
Cached Biology News:Carnivorous plants use pitchers of 'slimy saliva' to catch their prey 2Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center 2UK scientists lead China closer to carbon capture and storage 2
... Neogens enzyme-linked immunosorbent assay (ELISA) test ... screening devices for the detection of drugs ... kits are intended for forensic use only. ... be confirmed by a quantitative method such ...
... that noncovalently binds and inactivates neutral pancreatic RNase ... 1, T1, T2, H, U1, U2 or CL3. ... in that it has a more robust interaction ... in the absence of DTT or other reducing ...
...
UGT1A7 (E-15)...
Biology Products: